{
    "nctId": "NCT05635487",
    "briefTitle": "A Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients",
    "officialTitle": "A Phase II Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients",
    "overallStatus": "RECRUITING",
    "conditions": "HER2-positive Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 65,
    "primaryOutcomeMeasure": "Total pathological complete response (tpCR: ypT0-is/ypN0)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Female patients aged \u2265 18 but \u2264 75 years\n* Histologically confirmed to be HER2-positive invasive breast cancer\n* Treatment-naive patients with stage II-III\n* Eastern Cooperative Oncology Group (ECOG) score 0-1\n* Good level of organ function\n\nExclusion Criteria:\n\n* Previously received any anti-tumor therapy (chemotherapy, radiotherapy, molecular targeted therapy, endocrine therapy, etc.)\n* Received any other anti-tumor therapy at the same time\n* Bilateral breast cancer, inflammatory breast cancer or occult breast cancer\n* Stage IV breast cancer\n* With a history of any malignancies in the past 5 years, excluding cured cervical carcinoma in situ and melanoma skin cancer\n* Inability to swallow, chronic diarrhea, intestinal obstruction, and a variety of factors affecting drug administration and absorption\n* Participated in other drug clinical trials within 4 weeks before enrollment\n* History of allergies to the drug components of this protocol\n* Clinically significant pulmonary diseases\n* Clinically significant cardiovascular diseases\n* History of immunodeficiency\n* Active hepatitis and liver cirrhosis",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}